VERQUVO (vericiguat) Patient Assistance Program
Don’t let the high cost of brand specialty heart failure therapy disrupt your treatment. We help eligible patients access Verquvo (vericiguat) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Verquvo (vericiguat) is FDA-approved to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who have had a recent worsening heart failure event. It is a soluble guanylate cyclase (sGC) stimulator — a novel mechanism in HF therapy.
- Without assistance, Verquvo costs commonly run approximately $700–$900 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Verquvo for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Verquvo in the U.S. as of 2026. Verquvo is added to background guideline-directed medical therapy (GDMT) for HFrEF — which includes ARNi (Entresto, with generic now available 2025), beta-blockers (generic), MRA (spironolactone/eplerenone, generic), and SGLT2 inhibitors (Jardiance, Farxiga). Background generic GDMT remains the foundation; Verquvo is added in select patients with recent HF events.
What Is Verquvo Prescription Assistance Program?
The Verquvo Prescription Assistance Program is a manufacturer-sponsored initiative that provides Verquvo at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HFrEF patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, cardiology coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Verquvo costs roughly $700–$900/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$870 | Save ~$800/mo |
| CVS Pharmacy | ~$900 | Save ~$830/mo |
| Walmart | ~$740 | Save ~$670/mo |
| Costco | ~$720 | Save ~$650/mo |
Kroger | ~$750 | Save ~$680/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Verquvo Prescription Program?
The Patient Assistance Program is free to apply for and provides Verquvo at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Verquvo:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $700–$900 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Verquvo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Verquvo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Verquvo:
Verquvo (vericiguat) is a once-daily oral soluble guanylate cyclase (sGC) stimulator — a first-in-class mechanism for chronic heart failure with reduced ejection fraction. It is added to standard guideline-directed medical therapy (GDMT) in patients with a recent worsening heart failure event to reduce future cardiovascular death and HF hospitalization.
How Verquvo Works:
Vericiguat works by directly stimulating soluble guanylate cyclase (sGC) and sensitizing it to endogenous nitric oxide, which restores critical cGMP signaling that is typically impaired in heart failure with reduced ejection fraction (HFrEF). This process promotes vasodilation, reduces myocardial fibrosis and hypertrophy, and improves overall cardiovascular function. Clinical data from the VICTORIA trial demonstrated that this mechanism successfully reduces the combined risk of cardiovascular death and heart failure hospitalizations in high-risk patients. Ultimately, it counteracts the adverse vascular and cardiac remodeling associated with reduced cGMP production.
Form and use:
Verquvo is an oral medication taken once daily and must always be administered with food. Treatment begins at a starting dose of 2.5 mg and is doubled approximately every two weeks—first to 5 mg, then to the target maintenance dose of 10 mg once daily—as tolerated by the patient’s blood pressure and symptoms. For patients who experience swallowing difficulties, the tablets can be crushed and mixed with water.
Generic availability:
As of 2026, there is no generic version of Verquvo available in the United States. It is meant to be added to a patient’s optimized guideline-directed medical therapy (GDMT) for HFrEF. This background regimen typically includes available generic options like ARNis, beta-blockers, MRAs, and loop diuretics for congestion, alongside brand-name SGLT2 inhibitors like Jardiance or Farxiga.
Warnings:
Verquvo carries a strict warning for embryo-fetal toxicity, requiring a REMS program for females of reproductive potential that mandates pregnancy testing and effective contraception during use and for one month after. It can also cause hypotension, particularly when used with other blood pressure medications, as well as anemia from a decrease in hemoglobin. Furthermore, it is completely contraindicated with PDE5 inhibitors like sildenafil or other sGC stimulators due to the risk of additive hypotension and death, and it may interact with long-acting nitrates.
FAQ (Frequently Asked Questions)
How Much Does Verquvo Cost Without Insurance?
Verquvo costs approximately $700–$900 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Verquvo at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Who Is Verquvo For?
Verquvo is for adults with symptomatic chronic HFrEF (EF <45%) who have had a recent worsening heart failure event (recent HF hospitalization or need for outpatient IV diuretics). It is added to optimized standard therapy — not a replacement for ARNi/sacubitril-valsartan, beta-blockers, MRAs, or SGLT2 inhibitors. Patients without recent HF events were not studied in the VICTORIA trial.
Where Does Verquvo Fit With My Other HF Medications?
Verquvo is added to your standard heart failure regimen — not as a replacement. The ‘four pillars’ of HFrEF GDMT remain: ARNi (or ACEi/ARB), beta-blocker, MRA (spironolactone/eplerenone), and SGLT2 inhibitor. Verquvo is added on top of these in high-risk patients with recent HF events to further reduce events. Continue your background HF medications as prescribed.
Should I Be On An SGLT2 Inhibitor First?
Yes if not contraindicated — SGLT2 inhibitors (Jardiance, Farxiga) reduce mortality and HF hospitalization in HFrEF and are now considered foundational. If you have recent HF events on optimized therapy that already includes ARNi + beta-blocker + MRA + SGLT2i, Verquvo is reasonable additional therapy. If foundational therapies are not optimized, those should be addressed first.
Are There Drug Interactions I Should Know About?
Yes — important ones. PDE5 inhibitors (sildenafil/Viagra/Revatio, tadalafil/Cialis/Adcirca, vardenafil/Levitra, avanafil/Stendra) are CONTRAINDICATED due to risk of severe hypotension. Other sGC stimulators (riociguat/Adempas) are contraindicated. Use caution with long-acting nitrates and other antihypertensives. Tell every prescriber and pharmacist about Verquvo.
Can I Get Verquvo Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — optimizing your standard GDMT (generic ARNi, generic beta-blocker, generic MRA, plus SGLT2i with its own PAP if needed), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the American Heart Association, Heart Failure Society of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Verquvo, our team may be able to help you access assistance programs designed to make brand specialty HF therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.